Clinical Trial: Use of Rituximab Treatment in Addition to Standard Care for Newly Presenting Thrombotic Thrombocytopenic Purpura
Study Status: Withdrawn
Recruit Status: Withdrawn
Study Type: Interventional
Official Title: Use of Rituximab Treatment in Addition to Standard Care for Newly Presenting Thrombotic Thrombocytopenic Purpura
Brief Summary: The purpose is to evaluate safety and feasibility of the use of Rituximab as an adjunct to standard therapy (plasmapheresis + steroids) for patients with thrombotic thrombocytopenic purpura (TTP). This includes evaluating the rate and type of treatment failure.
Detailed Summary: With this study we hope to evaluate safety and feasibility of the use of Rituximab as an adjunct to standard therapy (plasmapheresis + steroids) for patients with thrombotic thrombocytopenic purpura (TTP). This includes evaluating the rate and type of treatment failure.
Sponsor: Weill Medical College of Cornell University
Current Primary Outcome: Failure to maintain the complete response until day 120; Non-protocol treatment for TTP, such as other immunosuppressive agents or splenectomy, reinstitution of plasma exchange within the first 90 days [ Time Frame: Four months ]
Original Primary Outcome:
Current Secondary Outcome:
Original Secondary Outcome:
Information By: Weill Medical College of Cornell University
Dates:
Date Received: November 7, 2005
Date Started: November 2005
Date Completion:
Last Updated: November 14, 2012
Last Verified: November 2012